BioPharmaPT
← All reports

Novartis AG — Rydapt EMA EPAR public assessment report (EMEA/H/C/004095, 2017)

Novartis AG · 2017 · EMA EPAR public assessment report · company profile →

Report summary

The EMA granted marketing authorization for Rydapt (midostaurin) on July 20, 2017, for newly diagnosed FLT3 mutation-positive acute myeloid leukaemia (AML) and advanced systemic mastocytosis (SM). Rydapt, a new therapeutic agent, targets FLT3 and KIT. Pivotal studies demonstrated significant efficacy: in FLT3-mutated AML, midostaurin improved overall survival and event-free survival compared to placebo. For advanced SM, it achieved notable overall response rates in a single-arm study. Pharmacokinetic analysis revealed time-dependent kinetics and CYP3A4 metabolism, with strong inhibitors/inducers significantly impacting exposure. Key safety concerns include myelosuppression, gastrointestinal events, and cardiac toxicities, particularly QT prolongation. A risk management plan addresses these identified and potential risks.

Key findings — cited to the page

Diarrhoea (all grades)74.8 %All sites · p.179
Diarrhoea (all grades)73.6 %All sites · p.179
Lipase increased (Grade 3/4 laboratory abnormality)17.6 % · p.187
Hyperglycaemia (Grade 3/4 laboratory abnormality)19 % · p.187
grade 3/4 hypotension (midostaurin vs placebo)10 vs 1 patients · p.199
Diarrhoea (Grade 3/4)14.5 %All sites · p.179
Absolute lymphocyte count decreased (Grade 3/4 laboratory abnormality)45.8 % · p.187
Grade 3-4 nausea (midostaurin)6.0 %D2201 · p.203
grade 3/4 febrile neutropenia44 % · p.199
ANC decreased (Grade 3/4 laboratory abnormality)26.8 % · p.187
grade 3/4 exfoliative dermatitis (midostaurin vs placebo)10 vs 1 patients · p.199
Diarrhoea (Grade 3/4)16.9 %All sites · p.179

Source: Novartis AG · License: EMA - reuse permitted with acknowledgement. Summary and findings are extracted from the published document; every figure cites its page. Informational only — not investment advice. Explore the Oncology library →

Novartis AG — Rydapt EMA EPAR public assessment report (EMEA/H/C/004095, 2017) — Summary & Key Findings | BioPharmaPT